Sasanuma H, Tsuda M, Morimoto S, et al. BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes. Proc Natl Acad Sci U S A. 2018;115(45):E10642-E10651. doi:10.1073/pnas.1803177115.
Shee K, Jiang A, Varn FS, et al. Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER breast cancer. FASEB J. 2019;33(2):1644-1657. doi:10.1096/fj.201801241R.
Ubellacker JM, Baryawno N, Severe N, et al. Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer. Cancer Res. 2018;78(18):5300-5314. doi:10.1158/0008-5472.CAN-18-0548.
Castaño Z, San Juan BP, Spiegel A, et al. IL-1β inflammatory response driven by primary breast cancer prevents metastasis-initiating cell colonization. Nat Cell Biol. 2018;20(9):1084-1097. doi:10.1038/s41556-018-0173-5.
Gallenne T, Ross KN, Visser NL, et al. Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer. Oncotarget. 2017;8(13):20572-20587. doi:10.18632/oncotarget.16244.
Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548(7668):471-475. doi:10.1038/nature23465.
Rheinbay E, Parasuraman P, Grimsby J, et al. Recurrent and functional regulatory mutations in breast cancer. Nature. 2017;547(7661):55-60. doi:10.1038/nature22992.
Krug K, Mertins P, Zhang B, et al. A Curated Resource for Phosphosite-specific Signature Analysis. Mol Cell Proteomics. 2019;18(3):576-593. doi:10.1074/mcp.TIR118.000943.
Kitajima S, Yoshida A, Kohno S, et al. The RB-IL-6 axis controls self-renewal and endocrine therapy resistance by fine-tuning mitochondrial activity. Oncogene. 2017;36(36):5145-5157. doi:10.1038/onc.2017.124.
Satpathy S, Jaehnig EJ, Krug K, et al. Microscaled proteogenomic methods for precision oncology. Nat Commun. 2020;11(1):532. doi:10.1038/s41467-020-14381-2.